This Blog Providing Global Business Information Reports Related To All Types Of Product And Services.

Welcome

Tuesday, 17 February 2015

NSCLC Therapeutics in Asia-Pacific Market to 2019 - New Research Report Published By Radiant Insights

Summary GBI Research has released its pharma research, "Epilepsy Therapeutics in Major Developed Markets to 2019 - New AEDs with Novel Mechanisms of Action Signal a Shift in Treatment Patterns", which provides in-depth analysis of epilepsy market within the eight major developed markets of the US, UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an estimation of the market size for 2012, along with market forecasts to 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis. The value of the epilepsy market in the major developed markets amounted to an estimated $3.4 billion in 2012 and is expected to register a Compound Annual Growth Rate (CAGR) of 3.9% to reach $4.5 billion by 2019. This modest growth is attributed to the recent approval of drugs with novel mechanisms of action that are expected to offer more therapeutic options to prescribers. The US takes major share of 55% of the global epilepsy market. In the US, three new anti-epileptic drugs have been approved since 2012: Trobalt, Aptiom, and Fycompa and another, brivaracetam, is expected also to be launched during the forecast period. Click for report details: http://www.radiantinsights.com/research/epilepsy-therapeutics-in-major-developed-markets-to-2019-new-aeds-with-novel-mechanisms-of-action-signal-a-shift-in-treatment-patterns Of these, Trobalt and Fycompa have novel mechanisms of action and improved safety and tolerability that elicited significant interest from prescribers. Continued uptake of second- and third-generation anti-epileptic drugs is also expected to contribute towards revenues in these eight regions. However, the epilepsy market could face the restricting influence of generic competition as a result of recent patent expiries in all major markets of two key branded drugs, Keppra and Lamictal. Scope - A brief introduction to epilepsy, including disease pathogenesis, risk factors, diagnosis and treatment options - In-depth analysis of major marketed products covering product performance, product life-cycle and a heat map depicting comparative analysis of safety and efficacy parameters - A comprehensive review of the epilepsy pipeline which includes individual analysis of promising late-stage pipeline drugs that are most likely to enter the market during the forecast period. The pipeline is analyzed on the basis of Phase distribution, molecule type and molecular target - Additional clinical trial analysis by Phase, trial size, trial duration and program failure rate for each molecule type and mechanism of action - Multi-scenario forecasts of the epilepsy market over the 2012-2019 period in the eight major developed markets

About Radiant InsightsRadiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions. For More Information Visit – Radiant InsightsContact:Michelle ThorasCorporate Sales Specialist, USARadiant Insights, IncPhone: 1-415-349-0058Toll Free: 1-888-202-9519Email: sales@radiantinsights.com